Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 229

1.

Prevalence of Vertebral Fractures in Children with Suspected Osteoporosis.

Kyriakou A, Shepherd S, Mason A, Ahmed SF.

J Pediatr. 2016 Dec;179:219-225. doi: 10.1016/j.jpeds.2016.08.075.

PMID:
27640353
2.
3.

Age Disparities in the Use of Steroid-sparing Therapy for Inflammatory Bowel Disease.

Govani SM, Wiitala WL, Stidham RW, Saini SD, Hou JK, Feagins LA, Sussman JB, Higgins PD, Waljee AK.

Inflamm Bowel Dis. 2016 Aug;22(8):1923-8. doi: 10.1097/MIB.0000000000000817.

PMID:
27416039
4.

Vitamin D in Health and Disease in Adolescents: When to Screen, Whom to Treat, and How to Treat.

Golden NH, Carey DE.

Adolesc Med State Art Rev. 2016 Spring;27(1):125-39. Review.

PMID:
27363237
5.

[THE DEFEAT OF BONE TISSUE IN CHILDREN WITH INFLAMMATORY BOWEL DISEASES].

Gabrusskaya TV.

Eksp Klin Gastroenterol. 2016;(2):70-8. Review. Russian.

PMID:
27301121
6.

Are Men at High Risk for Osteoporosis Underscreened? A Quality Improvement Project.

Jain S, Bilori B, Gupta A, Spanos P, Singh M.

Perm J. 2016 Winter;20(1):60-4. doi: 10.7812/TPP/14-190.

7.

[Pharmacological treatment of other types of secondary osteoporosis].

Okazaki R.

Nihon Rinsho. 2015 Oct;73(10):1740-5. Japanese.

PMID:
26529940
8.

[Inflammatory bowel disease and bone decreased bone mineral density].

Hisamatsu T, Wada Y, Kanai T.

Clin Calcium. 2015 Nov;25(11):1639-44. doi: CliCa151116391644. Japanese.

PMID:
26503868
9.

Increased levels of interleukin 31 (IL-31) in osteoporosis.

Ginaldi L, De Martinis M, Ciccarelli F, Saitta S, Imbesi S, Mannucci C, Gangemi S.

BMC Immunol. 2015 Oct 8;16:60. doi: 10.1186/s12865-015-0125-9.

10.

Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases.

Amarasekara DS, Yu J, Rho J.

J Immunol Res. 2015;2015:832127. doi: 10.1155/2015/832127. Review.

11.

Inflammatory signaling induced bone loss.

Goldring SR.

Bone. 2015 Nov;80:143-9. doi: 10.1016/j.bone.2015.05.024. Review.

PMID:
26027506
12.

Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Mirza F, Canalis E.

Eur J Endocrinol. 2015 Sep;173(3):R131-51. doi: 10.1530/EJE-15-0118. Review.

13.

[Update of recommendations for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions. Working Group on Osteoporosis and Mineral Metabolism of the Spanish Society of Endocrinology].

Reyes-García R, García-Martín A, Varsavsky M, Rozas-Moreno P, Cortés-Berdonces M, Luque-Fernández I, Gómez Sáez JM, Vidal Casariego A, Romero Muñoz M, Guadalix Iglesias S, Fernández García D, Jódar Gimeno E, Muñoz Torres M; en representación del Grupo de trabajo de osteoporosis y metabolismo mineral de la Sociedad Española de Endocrinología y Nutrición..

Endocrinol Nutr. 2015 May;62(5):e47-56. doi: 10.1016/j.endonu.2015.01.011. Spanish.

PMID:
25797189
14.

Risk factors for decreased bone mineral density in inflammatory bowel disease: A cross-sectional study.

Wada Y, Hisamatsu T, Naganuma M, Matsuoka K, Okamoto S, Inoue N, Yajima T, Kouyama K, Iwao Y, Ogata H, Hibi T, Abe T, Kanai T.

Clin Nutr. 2015 Dec;34(6):1202-9. doi: 10.1016/j.clnu.2015.01.003.

PMID:
25618799
15.

Piroxicam treatment augments bone abnormalities in interleukin-10 knockout mice.

Holgersen K, Dobie R, Farquharson C, vanʼt Hof R, Ahmed SF, Hansen AK, Holm TL.

Inflamm Bowel Dis. 2015 Feb;21(2):257-66. doi: 10.1097/MIB.0000000000000269.

PMID:
25569742
16.

The Role of Vitamin D in Inflammatory Bowel Disease.

Bancil AS, Poullis A.

Healthcare (Basel). 2015 May 27;3(2):338-50. doi: 10.3390/healthcare3020338. Review.

17.

Risks and predictors of osteoporosis in patients with inflammatory bowel diseases in an Asian population: a nationwide population-based cohort study.

Tsai MS, Lin CL, Tu YK, Lee PH, Kao CH.

Int J Clin Pract. 2015 Feb;69(2):235-41. doi: 10.1111/ijcp.12526.

PMID:
25472555
18.

Managing osteoporosis in ulcerative colitis: something new?

Piodi LP, Poloni A, Ulivieri FM.

World J Gastroenterol. 2014 Oct 21;20(39):14087-98. doi: 10.3748/wjg.v20.i39.14087. Review.

19.

Immortal time bias: a likely alternate explanation for the purported benefits of DXA Screening in ulcerative colitis.

Targownik LE.

Am J Gastroenterol. 2014 Oct;109(10):1689. doi: 10.1038/ajg.2014.234. No abstract available.

PMID:
25287099
20.

Prevalence of chronic narcotic use among children with inflammatory bowel disease.

Buckley JP, Cook SF, Allen JK, Kappelman MD.

Clin Gastroenterol Hepatol. 2015 Feb;13(2):310-315.e2. doi: 10.1016/j.cgh.2014.07.057.

PMID:
25117776
Items per page

Supplemental Content

Loading ...
Support Center